Guidance, NICE advice and quality standards in development | Guidance

Showing 251 to 260 of 389

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]	Technology appraisal guidance	23 July 2026
Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]	Technology appraisal guidance	TBC
Peezy Midstream for urine collection (MT446)	Medical technologies guidance	TBC
Pegcetacoplan for amyotrophic lateral sclerosis [TSID10594]	Technology appraisal guidance	TBC
Pegcetacoplan for treating complement 3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]	Technology appraisal guidance	18 June 2026
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021]	Technology appraisal guidance	TBC
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]	Technology appraisal guidance	29 October 2026
Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6473]	Technology appraisal guidance	TBC
Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma [ID6477]	Technology appraisal guidance	20 April 2026
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]	Technology appraisal guidance	TBC